Sugi Predict

Sugi Predict / Compounds / SCHEMBL518632

SCHEMBL518632

SCHEMBL518632

O=C(O)c1ccc(OC(F)(F)F)cc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 1/20 0.53
▸ AKR1C2 P52895 1/20 0.49
▸ AKR1C1 Q04828 1/20 0.49
▸ IGF2BP2 Q9Y6M1 1/20 0.47
▸ MRGPRX4 Q96LA9 2/20 0.46
▸ AURKA O14965 1/20 0.45
▸ TPX2 Q9ULW0 1/20 0.45
▸ KCNK2 O95069 1/20 0.45
▸ KCNK10 P57789 1/20 0.45
▸ FFAR4 Q5NUL3 4/20 0.45
▸ FFAR1 O14842 2/20 0.45
▸ DHODH Q02127 2/20 0.43
▸ PTGS1 P23219 1/20 0.43
▸ PTGS2 P35354 1/20 0.43
▸ EPHX2 P34913 1/20 0.43
▸ KDM5A P29375 1/20 0.43
▸ KDM4C Q9H3R0 1/20 0.43
▸ KDM5B Q9UGL1 1/20 0.43
▸ RARA P10276 1/20 0.43
▸ RARB P10826 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1697975 0.86 IGF2BP2 (0.50) PIM1AKR1C2AKR1C1IGF2BP2MRGPRX4
SCHEMBL22092981 0.84 DGAT1 (0.51) PIM1FFAR4FFAR1EPHX2
SCHEMBL30557826 0.84 MAOB (0.54) PIM1FFAR4FFAR1EPHX2
SCHEMBL17766955 0.84 MAOB (0.54) PIM1FFAR4FFAR1EPHX2
SCHEMBL16398416 0.84 ALDH1A1 (0.44) PIM1AKR1C2AKR1C1AURKATPX2
SCHEMBL2592316 0.84 RARB (0.45) PIM1EPHX2RARARARB
SCHEMBL20644248 0.83 CFTR (0.46) MRGPRX4EPHX2
SCHEMBL12586119 0.82 ALDH1A1 (0.55) PIM1AKR1C2AKR1C1IGF2BP2MRGPRX4
SCHEMBL30769853 0.82 ALDH1A1 (0.55) PIM1AKR1C2AKR1C1IGF2BP2MRGPRX4
SCHEMBL22497443 0.81 ALDH1A1 (0.57) PIM1AKR1C2AKR1C1IGF2BP2MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12281057-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-04-22 — — US disclosed
EP-3651752-B1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2024-11-20 — — EP disclosed
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-14 — — US disclosed
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-14 — — US disclosed
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-09-14 — — US disclosed
US-11603351-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-03-14 — — US disclosed
US-20230026271-A1 Piperazine Compounds for Inhibiting CPS1 EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-01-26 — — US disclosed
US-20230026271-A1 Piperazine Compounds for Inhibiting CPS1 EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-01-26 — — US disclosed
EP-4061803-A1 PIPERAZINE COMPOUNDS FOR INHIBITING CPS1 Eisai R&D Management Co., Ltd. (JP) 2022-09-28 — — EP disclosed
CN-114981247-A Piperazine compounds for inhibiting CPS1 卫材R&D管理有限公司 2022-08-30 — — CN disclosed
CN-102015677-A Pyrimidinone derivatives and methods of use thereof SCHERING CORP 2011-04-13 — — CN disclosed
WO-2010090737-A1 PYRIDAZINONE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-12 — — WO disclosed
US-20100197651-A1 Pyridazinone compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-05 — — US disclosed
US-20100197651-A1 Pyridazinone compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-05 — — US disclosed
US-20100197651-A1 Pyridazinone compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-05 — — US disclosed
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION 2010-07-29 — — US disclosed
WO-2010056999-A1 ENANTIOMERICALLY ENRICHED ARYLOAZOL- 2 -YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS MERIAL LIMITED (US) 2010-05-20 — — WO disclosed
US-20100125089-A1 ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF MERIAL, INC. 2010-05-20 — — US disclosed
EP-2148869-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2010-02-03 — — EP disclosed
WO-2008130581-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2008-10-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603351-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A PIM1 4149/4885AKR1C2 3249/4885AKR1C1 3552/4885
US-20230026271-A1 Piperazine Compounds for Inhibiting CPS1 CPS1, CPSF1, CPSF7 PIM1 2153/4885AKR1C2 3823/4885AKR1C1 3535/4885
US-20100125089-A1 ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF CYP4B1, NPY4R, CYP4X1 PIM1 2646/4885AKR1C2 997/4885AKR1C1 1007/4885
US-20100190687-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF GPR119, GCGR, GPR65 PIM1 2365/4885AKR1C2 958/4885AKR1C1 1188/4885
US-20100197651-A1 Pyridazinone compounds PDE3A, PDE5A, PDE3B PIM1 2391/4885AKR1C2 939/4885AKR1C1 820/4885
US-20230286907-A1 CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS TRPV1, SCN2A, SCN10A PIM1 4149/4885AKR1C2 3249/4885AKR1C1 3552/4885
US-12281057-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A PIM1 4149/4885AKR1C2 3249/4885AKR1C1 3552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.